Susquehanna Fundamental Investments, LLC Fibrogen Inc Transaction History

Susquehanna Fundamental Investments, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$11.4 - $14.6 $1.04 Million - $1.34 Million	-91,623 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$9.93 - $15.39 $414,259 - $642,040	-41,718 Reduced 31.29%	91,623 $1.29 Million
Q3 2021 Nov 15, 2021	BUY	$10.18 - $26.64 $964,239 - $2.52 Million	94,719 Added 245.25%	133,341 $1.36 Million
Q2 2021 Aug 11, 2021	BUY	$18.57 - $35.68 $717,210 - $1.38 Million	38,622 New	38,622 $1.03 Million
Q1 2021 May 17, 2021	SELL	$31.0 - $55.72 $1.43 Million - $2.56 Million	-45,990 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$37.09 - $48.97 $270,757 - $357,481	-7,300 Reduced 13.7%	45,990 $1.71 Million
Q3 2020 Nov 16, 2020	BUY	$40.47 - $45.5 $1.38 Million - $1.56 Million	34,190 Added 179.01%	53,290 $2.19 Million
Q2 2020 Aug 14, 2020	BUY	$32.57 - $42.83 $622,087 - $818,053	19,100 New	19,100 $774,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.